NOACs are new oral anticoagulants that are novel alternative options for the treatment of thromboembolic disease. They mainly include factor IIa inhibitors, such as dabigatranate, with factor Xa inhibitors, such as rivaroxaban. Compared with warfarin, NOAC has the advantages of fixed-dose therapy that can be used without routine anticoagulation monitoring, less interaction with food and other drugs, etc. The main clinical application is to replace warfarin for patients with non-valvular atrial fibrillation. 1. Factor IIa inhibitors: the representative drug dabigatranate is a precursor drug, which competitively inhibits thrombin after conversion to dabigatran in vivo, with low bioavailability and generally Encapsulated in tartaric acid to increase absorption. Once bleeding occurs after the drug is used, the anticoagulant effect can be inhibited by the specific antagonist idaselizumab, which has 350 times the affinity for dabigatran than thrombin; 2. Factor Xa inhibitors: Rivaroxaban, apixaban and edoxaban are active drugs with high bioavailability, which exert anticoagulant effects by competitively binding to the coagulation factor X site.